PCGF3 CRISPR/Cas9 KO Plasmid (h): sc-405260
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PCGF3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PCGF3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PCGF3 CRISPR/Cas9 KO Plasmid (h) | sc-405260 | 20 µg | $397.00 |
Overview
PCGF3 (polycomb group ring finger 3) is a core component of non-canonical Polycomb repressive complex 1 (PRC1), functioning as an E3 ubiquitin ligase in conjunction with RING1A/RING1B to catalyze histone H2A monoubiquitination (H2AK119ub). Through this activity, PCGF3 contributes to Polycomb-mediated transcriptional repression, epigenetic memory, and chromatin compaction that help coordinate developmental gene expression programs and cell fate decisions. PCGF3-containing PRC1 complexes intersect with broader chromatin regulatory networks, including Polycomb/Trithorax balance and crosstalk with PRC2-dependent H3K27 methylation. Dysregulation of Polycomb signaling and PRC1 subunit composition is frequently implicated in aberrant gene silencing and transcriptional reprogramming observed in cancer and other disorders with epigenetic etiology, motivating mechanistic studies of PCGF3 function in human cells.
PCGF3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PCGF3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PCGF3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PCGF3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PCGF3 protein expression.
This CRISPR knockout system enables efficient generation of PCGF3-deficient cell models for investigation of PCGF3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PCGF3 exon(s) critical for PCGF3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PCGF3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PCGF3 CRISPR/Cas9 KO Plasmid (h) and PCGF3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PCGF3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PCGF3 HDR Plasmid (h) and PCGF3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PCGF3 homology arms to support homology-directed repair at defined PCGF3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.